Combining antibody therapies for cancer treatments to innovate Biomedical science
Event Summary:
In the Life Science industry, companies across the World are looking at targets to find new innovative treatment regimes in the field of oncology. Immunotherapy is one of the most promising areas within biomedical science to successfully identify new targets for cancer treatments in the human body. Antibodies hold most promise in the treatment of cancer due to its capabilities to activate the immune system.
Today, most pharmaceutical and biotechnology companies integrate antibody therapies and technologies for new drugs in order to personalise and provide better healthcare for cancer patients. By capitalising on antibodies, biopharmaceuticals are able to provide efficient cancer therapies and diagnostics with high margins to the market worldwide.
This international one day conference will provide your R & D organisation with a platform to harness the capabilities of antibodies to develop new and innovative cancer drugs. The speaker panel, which has expertise from Genmab, GSK Biologicals, Micromet, Affimed Therapeutics, Glycart Biotechnology (Roche), BioInvent and University Hospital Zurich will present the best strategies to successfully commercialise your scientific discoveries in a competitive business environment, the global Life Science industry.
View the web site for update news:
http://www.labinnovator.com/events/events-lio24.html
Organiser: Lab Innovator
Contact info: + 45 3313 6250